First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...
AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results